Blueshift Asset Management LLC Sells 90,922 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

Blueshift Asset Management LLC lessened its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 37.1% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 154,091 shares of the company's stock after selling 90,922 shares during the period. Hims & Hers Health accounts for 1.4% of Blueshift Asset Management LLC's portfolio, making the stock its 4th largest position. Blueshift Asset Management LLC owned 0.07% of Hims & Hers Health worth $3,726,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Crewe Advisors LLC bought a new position in Hims & Hers Health during the 4th quarter worth approximately $28,000. Raleigh Capital Management Inc. raised its holdings in Hims & Hers Health by 1,100.0% in the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after purchasing an additional 1,100 shares during the period. Blume Capital Management Inc. boosted its position in shares of Hims & Hers Health by 100.0% during the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after purchasing an additional 600 shares in the last quarter. Smartleaf Asset Management LLC grew its holdings in shares of Hims & Hers Health by 4,415.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock valued at $36,000 after buying an additional 1,413 shares during the period. Finally, US Bancorp DE increased its position in shares of Hims & Hers Health by 346.7% in the 4th quarter. US Bancorp DE now owns 1,943 shares of the company's stock valued at $47,000 after buying an additional 1,508 shares in the last quarter. Institutional investors and hedge funds own 63.52% of the company's stock.

Remove Ads

Insider Buying and Selling

In related news, insider Michael Chi sold 7,259 shares of Hims & Hers Health stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $24.07, for a total transaction of $174,724.13. Following the completion of the transaction, the insider now owns 193,601 shares in the company, valued at approximately $4,659,976.07. This trade represents a 3.61 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Soleil Boughton sold 268,932 shares of the business's stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $27.75, for a total value of $7,462,863.00. Following the transaction, the insider now directly owns 169,803 shares in the company, valued at approximately $4,712,033.25. This trade represents a 61.30 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 1,015,547 shares of company stock worth $36,146,450. Insiders own 17.71% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on HIMS. Needham & Company LLC boosted their target price on Hims & Hers Health from $31.00 to $61.00 and gave the company a "buy" rating in a research note on Tuesday, February 25th. Piper Sandler lifted their price objective on Hims & Hers Health from $24.00 to $35.00 and gave the company a "neutral" rating in a report on Tuesday, February 25th. Truist Financial increased their target price on Hims & Hers Health from $24.00 to $39.00 and gave the stock a "hold" rating in a research note on Wednesday, February 26th. Canaccord Genuity Group lifted their price target on shares of Hims & Hers Health from $38.00 to $68.00 and gave the company a "buy" rating in a research note on Wednesday, February 19th. Finally, Bank of America increased their price objective on shares of Hims & Hers Health from $21.00 to $22.00 and gave the stock an "underperform" rating in a research report on Tuesday, March 18th. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $37.31.

Hims & Hers Health Trading Up 7.5 %

Shares of Hims & Hers Health stock traded up $2.62 during trading hours on Monday, reaching $37.37. 26,319,367 shares of the company's stock were exchanged, compared to its average volume of 13,886,340. The company has a 50 day moving average of $39.44 and a two-hundred day moving average of $29.05. The stock has a market cap of $8.30 billion, a P/E ratio of 84.92 and a beta of 1.37. Hims & Hers Health, Inc. has a fifty-two week low of $11.20 and a fifty-two week high of $72.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings results on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, beating analysts' consensus estimates of $0.09 by $0.02. The firm had revenue of $481.14 million during the quarter, compared to the consensus estimate of $494.56 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. As a group, analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.